Eur J Cancer:Darolutamide可显著改善非转移性去势抵抗性前列腺癌患者的健康相关生活质量

2021-08-02 Nebula MedSci原创

Darolutamide可通过显著延迟前列腺癌特异性生活质量和疾病相关症状恶化的时间来维持患者的HRQoL

前列腺癌是男性第二大常见的恶性肿瘤,也是导致死亡的主要原因。在2018年,全球共有36万多男性死于前列腺癌。

雄激素剥夺疗法 (ADT) 是前列腺癌患者初次治疗后复发的标准防治的一部分。在ARAMIS试验中,Darolutamide(一种非甾体雄激素受体抑制剂)联合雄激素剥夺疗法(ADT)相比安慰剂联合ADT可明显延长非转移性去势抵抗性前列腺癌(nmCRPC)患者的无转移生存期(MFS)、总生存期(OS)和疼痛进展的时间。

本文报告了对ARAMIS试验患者报告的健康相关生活质量(HRQoL)结果的分析。

ARAMIS试验是一项双盲的、安慰剂为对照的3期临床试验,nmCRPC患者随机接受ADT+Darolutamide(n=955)或ADT+安慰剂(n=554)。主要终点是MFS;次要终点包括OS和疼痛进展的时间。在本次分析中,采用癌症治疗功能评估-前列腺癌 (FACT-P) 的前列腺癌亚量表(PCS)和欧洲癌症研究和治疗组织前列腺癌生活质量问卷模块 (EORTC QLQ-PR25) 亚量表对HRQoL的恶化时间进行评估。

FACT-P PCS和EORTC QLQ-PR25评分的恶化时间

主分析结果显示,Darolutamide相比安慰剂明显延长了疼痛进展时间(FACT-P PCS;HR 0.80, 95%CI 0.70–0.91; P=0.0005)。根据EORTC QLQ-PR25评估,Darolutamide还可相比安慰剂能显著延长泌尿系统和肠道症状的恶化时间(泌尿:HR 0.64, 95%CI 0.54–0.76; P<0.0001;肠道:HR 0.78, 95%CI 0.66–0.92; P=0.0027)。此外,两组间激素治疗相关症状恶化的时间相似。

总之,在无症状的nmCRPC患者中,与安慰剂相比,Darolutamide可通过显著延迟前列腺癌特异性生活质量和疾病相关症状恶化的时间来维持患者的HRQoL

原始出处:

Smith Matthew R,Shore Neal,Tammela Teuvo L et al. Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial.[J] .Eur J Cancer, 2021, 154: 138-146.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1819696, encodeId=d8be1819696c0, content=<a href='/topic/show?id=b018996931d' target=_blank style='color:#2F92EE;'>#非转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99693, encryptionId=b018996931d, topicName=非转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jun 03 21:57:25 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666089, encodeId=751716660899a, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Fri Dec 17 02:57:25 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080169, encodeId=c0a9208016994, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99694, encryptionId=fc8c9969495, topicName=非转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Aug 10 13:57:25 CST 2021, time=2021-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342172, encodeId=4a2513421e263, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37234, encryptionId=da143e23485, topicName=去势抵抗性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386810, encodeId=6c89138681038, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423380, encodeId=6d4c142338086, content=<a href='/topic/show?id=48e55e0461' target=_blank style='color:#2F92EE;'>#darolutamide#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5704, encryptionId=48e55e0461, topicName=darolutamide)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ab13776446, createdName=yangcx0916, createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459345, encodeId=6ffd14593456c, content=<a href='/topic/show?id=3fc49969667' target=_blank style='color:#2F92EE;'>#非转移性去势抵抗性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99696, encryptionId=3fc49969667, topicName=非转移性去势抵抗性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0a76134556, createdName=tonychen23, createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522213, encodeId=062e15222135d, content=<a href='/topic/show?id=d08e2e894e7' target=_blank style='color:#2F92EE;'>#健康相关生活质量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27894, encryptionId=d08e2e894e7, topicName=健康相关生活质量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd0411427202, createdName=yilong5287546, createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041057, encodeId=b8b0104105e57, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Aug 02 23:57:25 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004755, encodeId=2b9b1004e55b5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2ae5482421, createdName=ms4000000880766766, createdTime=Mon Aug 02 21:36:07 CST 2021, time=2021-08-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1819696, encodeId=d8be1819696c0, content=<a href='/topic/show?id=b018996931d' target=_blank style='color:#2F92EE;'>#非转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99693, encryptionId=b018996931d, topicName=非转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jun 03 21:57:25 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666089, encodeId=751716660899a, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Fri Dec 17 02:57:25 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080169, encodeId=c0a9208016994, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99694, encryptionId=fc8c9969495, topicName=非转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Aug 10 13:57:25 CST 2021, time=2021-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342172, encodeId=4a2513421e263, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37234, encryptionId=da143e23485, topicName=去势抵抗性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386810, encodeId=6c89138681038, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423380, encodeId=6d4c142338086, content=<a href='/topic/show?id=48e55e0461' target=_blank style='color:#2F92EE;'>#darolutamide#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5704, encryptionId=48e55e0461, topicName=darolutamide)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ab13776446, createdName=yangcx0916, createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459345, encodeId=6ffd14593456c, content=<a href='/topic/show?id=3fc49969667' target=_blank style='color:#2F92EE;'>#非转移性去势抵抗性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99696, encryptionId=3fc49969667, topicName=非转移性去势抵抗性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0a76134556, createdName=tonychen23, createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522213, encodeId=062e15222135d, content=<a href='/topic/show?id=d08e2e894e7' target=_blank style='color:#2F92EE;'>#健康相关生活质量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27894, encryptionId=d08e2e894e7, topicName=健康相关生活质量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd0411427202, createdName=yilong5287546, createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041057, encodeId=b8b0104105e57, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Aug 02 23:57:25 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004755, encodeId=2b9b1004e55b5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2ae5482421, createdName=ms4000000880766766, createdTime=Mon Aug 02 21:36:07 CST 2021, time=2021-08-02, status=1, ipAttribution=)]
    2021-12-17 yige2012
  3. [GetPortalCommentsPageByObjectIdResponse(id=1819696, encodeId=d8be1819696c0, content=<a href='/topic/show?id=b018996931d' target=_blank style='color:#2F92EE;'>#非转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99693, encryptionId=b018996931d, topicName=非转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jun 03 21:57:25 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666089, encodeId=751716660899a, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Fri Dec 17 02:57:25 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080169, encodeId=c0a9208016994, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99694, encryptionId=fc8c9969495, topicName=非转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Aug 10 13:57:25 CST 2021, time=2021-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342172, encodeId=4a2513421e263, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37234, encryptionId=da143e23485, topicName=去势抵抗性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386810, encodeId=6c89138681038, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423380, encodeId=6d4c142338086, content=<a href='/topic/show?id=48e55e0461' target=_blank style='color:#2F92EE;'>#darolutamide#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5704, encryptionId=48e55e0461, topicName=darolutamide)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ab13776446, createdName=yangcx0916, createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459345, encodeId=6ffd14593456c, content=<a href='/topic/show?id=3fc49969667' target=_blank style='color:#2F92EE;'>#非转移性去势抵抗性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99696, encryptionId=3fc49969667, topicName=非转移性去势抵抗性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0a76134556, createdName=tonychen23, createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522213, encodeId=062e15222135d, content=<a href='/topic/show?id=d08e2e894e7' target=_blank style='color:#2F92EE;'>#健康相关生活质量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27894, encryptionId=d08e2e894e7, topicName=健康相关生活质量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd0411427202, createdName=yilong5287546, createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041057, encodeId=b8b0104105e57, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Aug 02 23:57:25 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004755, encodeId=2b9b1004e55b5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2ae5482421, createdName=ms4000000880766766, createdTime=Mon Aug 02 21:36:07 CST 2021, time=2021-08-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1819696, encodeId=d8be1819696c0, content=<a href='/topic/show?id=b018996931d' target=_blank style='color:#2F92EE;'>#非转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99693, encryptionId=b018996931d, topicName=非转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jun 03 21:57:25 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666089, encodeId=751716660899a, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Fri Dec 17 02:57:25 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080169, encodeId=c0a9208016994, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99694, encryptionId=fc8c9969495, topicName=非转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Aug 10 13:57:25 CST 2021, time=2021-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342172, encodeId=4a2513421e263, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37234, encryptionId=da143e23485, topicName=去势抵抗性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386810, encodeId=6c89138681038, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423380, encodeId=6d4c142338086, content=<a href='/topic/show?id=48e55e0461' target=_blank style='color:#2F92EE;'>#darolutamide#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5704, encryptionId=48e55e0461, topicName=darolutamide)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ab13776446, createdName=yangcx0916, createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459345, encodeId=6ffd14593456c, content=<a href='/topic/show?id=3fc49969667' target=_blank style='color:#2F92EE;'>#非转移性去势抵抗性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99696, encryptionId=3fc49969667, topicName=非转移性去势抵抗性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0a76134556, createdName=tonychen23, createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522213, encodeId=062e15222135d, content=<a href='/topic/show?id=d08e2e894e7' target=_blank style='color:#2F92EE;'>#健康相关生活质量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27894, encryptionId=d08e2e894e7, topicName=健康相关生活质量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd0411427202, createdName=yilong5287546, createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041057, encodeId=b8b0104105e57, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Aug 02 23:57:25 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004755, encodeId=2b9b1004e55b5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2ae5482421, createdName=ms4000000880766766, createdTime=Mon Aug 02 21:36:07 CST 2021, time=2021-08-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1819696, encodeId=d8be1819696c0, content=<a href='/topic/show?id=b018996931d' target=_blank style='color:#2F92EE;'>#非转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99693, encryptionId=b018996931d, topicName=非转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jun 03 21:57:25 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666089, encodeId=751716660899a, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Fri Dec 17 02:57:25 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080169, encodeId=c0a9208016994, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99694, encryptionId=fc8c9969495, topicName=非转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Aug 10 13:57:25 CST 2021, time=2021-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342172, encodeId=4a2513421e263, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37234, encryptionId=da143e23485, topicName=去势抵抗性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386810, encodeId=6c89138681038, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423380, encodeId=6d4c142338086, content=<a href='/topic/show?id=48e55e0461' target=_blank style='color:#2F92EE;'>#darolutamide#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5704, encryptionId=48e55e0461, topicName=darolutamide)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ab13776446, createdName=yangcx0916, createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459345, encodeId=6ffd14593456c, content=<a href='/topic/show?id=3fc49969667' target=_blank style='color:#2F92EE;'>#非转移性去势抵抗性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99696, encryptionId=3fc49969667, topicName=非转移性去势抵抗性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0a76134556, createdName=tonychen23, createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522213, encodeId=062e15222135d, content=<a href='/topic/show?id=d08e2e894e7' target=_blank style='color:#2F92EE;'>#健康相关生活质量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27894, encryptionId=d08e2e894e7, topicName=健康相关生活质量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd0411427202, createdName=yilong5287546, createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041057, encodeId=b8b0104105e57, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Aug 02 23:57:25 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004755, encodeId=2b9b1004e55b5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2ae5482421, createdName=ms4000000880766766, createdTime=Mon Aug 02 21:36:07 CST 2021, time=2021-08-02, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1819696, encodeId=d8be1819696c0, content=<a href='/topic/show?id=b018996931d' target=_blank style='color:#2F92EE;'>#非转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99693, encryptionId=b018996931d, topicName=非转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jun 03 21:57:25 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666089, encodeId=751716660899a, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Fri Dec 17 02:57:25 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080169, encodeId=c0a9208016994, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99694, encryptionId=fc8c9969495, topicName=非转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Aug 10 13:57:25 CST 2021, time=2021-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342172, encodeId=4a2513421e263, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37234, encryptionId=da143e23485, topicName=去势抵抗性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386810, encodeId=6c89138681038, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423380, encodeId=6d4c142338086, content=<a href='/topic/show?id=48e55e0461' target=_blank style='color:#2F92EE;'>#darolutamide#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5704, encryptionId=48e55e0461, topicName=darolutamide)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ab13776446, createdName=yangcx0916, createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459345, encodeId=6ffd14593456c, content=<a href='/topic/show?id=3fc49969667' target=_blank style='color:#2F92EE;'>#非转移性去势抵抗性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99696, encryptionId=3fc49969667, topicName=非转移性去势抵抗性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0a76134556, createdName=tonychen23, createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522213, encodeId=062e15222135d, content=<a href='/topic/show?id=d08e2e894e7' target=_blank style='color:#2F92EE;'>#健康相关生活质量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27894, encryptionId=d08e2e894e7, topicName=健康相关生活质量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd0411427202, createdName=yilong5287546, createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041057, encodeId=b8b0104105e57, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Aug 02 23:57:25 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004755, encodeId=2b9b1004e55b5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2ae5482421, createdName=ms4000000880766766, createdTime=Mon Aug 02 21:36:07 CST 2021, time=2021-08-02, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1819696, encodeId=d8be1819696c0, content=<a href='/topic/show?id=b018996931d' target=_blank style='color:#2F92EE;'>#非转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99693, encryptionId=b018996931d, topicName=非转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jun 03 21:57:25 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666089, encodeId=751716660899a, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Fri Dec 17 02:57:25 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080169, encodeId=c0a9208016994, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99694, encryptionId=fc8c9969495, topicName=非转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Aug 10 13:57:25 CST 2021, time=2021-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342172, encodeId=4a2513421e263, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37234, encryptionId=da143e23485, topicName=去势抵抗性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386810, encodeId=6c89138681038, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423380, encodeId=6d4c142338086, content=<a href='/topic/show?id=48e55e0461' target=_blank style='color:#2F92EE;'>#darolutamide#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5704, encryptionId=48e55e0461, topicName=darolutamide)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ab13776446, createdName=yangcx0916, createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459345, encodeId=6ffd14593456c, content=<a href='/topic/show?id=3fc49969667' target=_blank style='color:#2F92EE;'>#非转移性去势抵抗性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99696, encryptionId=3fc49969667, topicName=非转移性去势抵抗性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0a76134556, createdName=tonychen23, createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522213, encodeId=062e15222135d, content=<a href='/topic/show?id=d08e2e894e7' target=_blank style='color:#2F92EE;'>#健康相关生活质量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27894, encryptionId=d08e2e894e7, topicName=健康相关生活质量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd0411427202, createdName=yilong5287546, createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041057, encodeId=b8b0104105e57, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Aug 02 23:57:25 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004755, encodeId=2b9b1004e55b5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2ae5482421, createdName=ms4000000880766766, createdTime=Mon Aug 02 21:36:07 CST 2021, time=2021-08-02, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1819696, encodeId=d8be1819696c0, content=<a href='/topic/show?id=b018996931d' target=_blank style='color:#2F92EE;'>#非转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99693, encryptionId=b018996931d, topicName=非转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jun 03 21:57:25 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666089, encodeId=751716660899a, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Fri Dec 17 02:57:25 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080169, encodeId=c0a9208016994, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99694, encryptionId=fc8c9969495, topicName=非转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Aug 10 13:57:25 CST 2021, time=2021-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342172, encodeId=4a2513421e263, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37234, encryptionId=da143e23485, topicName=去势抵抗性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386810, encodeId=6c89138681038, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423380, encodeId=6d4c142338086, content=<a href='/topic/show?id=48e55e0461' target=_blank style='color:#2F92EE;'>#darolutamide#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5704, encryptionId=48e55e0461, topicName=darolutamide)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ab13776446, createdName=yangcx0916, createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459345, encodeId=6ffd14593456c, content=<a href='/topic/show?id=3fc49969667' target=_blank style='color:#2F92EE;'>#非转移性去势抵抗性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99696, encryptionId=3fc49969667, topicName=非转移性去势抵抗性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0a76134556, createdName=tonychen23, createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522213, encodeId=062e15222135d, content=<a href='/topic/show?id=d08e2e894e7' target=_blank style='color:#2F92EE;'>#健康相关生活质量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27894, encryptionId=d08e2e894e7, topicName=健康相关生活质量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd0411427202, createdName=yilong5287546, createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041057, encodeId=b8b0104105e57, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Aug 02 23:57:25 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004755, encodeId=2b9b1004e55b5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2ae5482421, createdName=ms4000000880766766, createdTime=Mon Aug 02 21:36:07 CST 2021, time=2021-08-02, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1819696, encodeId=d8be1819696c0, content=<a href='/topic/show?id=b018996931d' target=_blank style='color:#2F92EE;'>#非转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99693, encryptionId=b018996931d, topicName=非转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jun 03 21:57:25 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666089, encodeId=751716660899a, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Fri Dec 17 02:57:25 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080169, encodeId=c0a9208016994, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99694, encryptionId=fc8c9969495, topicName=非转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Aug 10 13:57:25 CST 2021, time=2021-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342172, encodeId=4a2513421e263, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37234, encryptionId=da143e23485, topicName=去势抵抗性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386810, encodeId=6c89138681038, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423380, encodeId=6d4c142338086, content=<a href='/topic/show?id=48e55e0461' target=_blank style='color:#2F92EE;'>#darolutamide#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5704, encryptionId=48e55e0461, topicName=darolutamide)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ab13776446, createdName=yangcx0916, createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459345, encodeId=6ffd14593456c, content=<a href='/topic/show?id=3fc49969667' target=_blank style='color:#2F92EE;'>#非转移性去势抵抗性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99696, encryptionId=3fc49969667, topicName=非转移性去势抵抗性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0a76134556, createdName=tonychen23, createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522213, encodeId=062e15222135d, content=<a href='/topic/show?id=d08e2e894e7' target=_blank style='color:#2F92EE;'>#健康相关生活质量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27894, encryptionId=d08e2e894e7, topicName=健康相关生活质量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd0411427202, createdName=yilong5287546, createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041057, encodeId=b8b0104105e57, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Aug 02 23:57:25 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004755, encodeId=2b9b1004e55b5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2ae5482421, createdName=ms4000000880766766, createdTime=Mon Aug 02 21:36:07 CST 2021, time=2021-08-02, status=1, ipAttribution=)]
    2021-08-02 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1819696, encodeId=d8be1819696c0, content=<a href='/topic/show?id=b018996931d' target=_blank style='color:#2F92EE;'>#非转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99693, encryptionId=b018996931d, topicName=非转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jun 03 21:57:25 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666089, encodeId=751716660899a, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Fri Dec 17 02:57:25 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080169, encodeId=c0a9208016994, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99694, encryptionId=fc8c9969495, topicName=非转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Aug 10 13:57:25 CST 2021, time=2021-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342172, encodeId=4a2513421e263, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37234, encryptionId=da143e23485, topicName=去势抵抗性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386810, encodeId=6c89138681038, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423380, encodeId=6d4c142338086, content=<a href='/topic/show?id=48e55e0461' target=_blank style='color:#2F92EE;'>#darolutamide#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5704, encryptionId=48e55e0461, topicName=darolutamide)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ab13776446, createdName=yangcx0916, createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459345, encodeId=6ffd14593456c, content=<a href='/topic/show?id=3fc49969667' target=_blank style='color:#2F92EE;'>#非转移性去势抵抗性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99696, encryptionId=3fc49969667, topicName=非转移性去势抵抗性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0a76134556, createdName=tonychen23, createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522213, encodeId=062e15222135d, content=<a href='/topic/show?id=d08e2e894e7' target=_blank style='color:#2F92EE;'>#健康相关生活质量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27894, encryptionId=d08e2e894e7, topicName=健康相关生活质量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd0411427202, createdName=yilong5287546, createdTime=Wed Aug 04 11:57:25 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041057, encodeId=b8b0104105e57, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Aug 02 23:57:25 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004755, encodeId=2b9b1004e55b5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2ae5482421, createdName=ms4000000880766766, createdTime=Mon Aug 02 21:36:07 CST 2021, time=2021-08-02, status=1, ipAttribution=)]
    2021-08-02 ms4000000880766766

    学习了

    0

相关资讯

Neurology:脑动静脉畸形患者的长期健康相关生活质量

通过仔细选择患者,SPC B类患者可获得与SPC A类患者相同的HRQOL,提前是手术成功。应采取有效治疗以防止完全AVM闭塞,预防多次出血事件。AVM患者的术后治疗应侧重于预防抑郁症状、焦虑和癫痫发作。研究人员鼓励其他研究小组使用HRQOL工具充分了解神经病学和神经外科疾病对患者HRQOL的影响。

European Urology:膀胱癌患者的生活质量如何?问卷提示性功能障碍成很大困扰

与普通人群和其他常见癌症患者报告的HRQOL相比,膀胱癌患者的HRQOL更差。

原发性胆汁性肝硬化,及其生活质量量表(PBC-40)介绍

原发性胆汁性肝硬化(primary biliary cirrhosis, PBC)是肝内胆管进行性破坏并以慢性胆汁淤积为主要特征的不明原因的疾病。原发性胆汁性肝硬化常与其他免疫性疾病如类风

JAMA Ophthalmology:全球用眼健康和生活质量评估,及早干预很重要!

视力损害和眼部疾病与生活质量较低相关,眼科干预可显著改善生活质量。在全球范围内加大干预力度,如白内障手术、屈光不正矫正和抗vegf治疗,有可能改善全世界数百万人的生活质量。

ESMO Open:健康相关生活质量有助于预测卵巢癌患者的短期死亡风险!

健康相关生活质量(HRQoL)是一种患者自我报告的预后指标,通常用于衡量治疗效果,是患者存活期的一个独立的预测因素。

Lancet Oncol:奥拉帕利长期维持治疗对患者生活质量的影响

在3期SOLO1试验中,奥拉帕利维持治疗为新确诊的携带BRCA突变的经以铂类为基础的化疗后获得缓解的晚期卵巢癌患者提供了相比安慰剂组明显延长的无进展生存期益处。